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Background: Intranasal corticosteroids (INS) are recommended as
ﬁrst-line therapy for allergic rhinitis. To date, no studies have evalu-
ated the impact of an INS delivery system on patient satisfaction.
Unless patients use a medication appropriately and consistently, they
will not fully beneﬁt from its therapeutic effects.
Objective: To determine whether the characteristics of the mometa-
sone furoate nasal spray (MFNS) delivery device are an impediment
to its use.
Methods/Database: A random sample of preidentiﬁed MFNS users
was recruited through e-mail (N = 1544). In online interviews, par-
ticipants were asked about MFNS ease of use and attributes.
Results: Ninety-eight percent of respondents reported that MFNS is
easy to use, and 96% said that the applicator is easy to administer.
Nearly all elderly users and users with arthritis said that the applicator
ﬁts comfortably in the nostril (96% and 97%, respectively) and is
appropriately sized (97% and 96%, respectively); 96% of pediatric
users agreed that the applicator ﬁts comfortably. All users said the
applicator’s ease of use and comfortable ﬁt were its most important
attributes.
Conclusions: The perceived ease of use of MFNS may help providers
appropriately treat patients with allergic rhinitis and may improve
patient adherence to INS use.
Key Words: ease of use, mometasone furoate, survey, allergic
rhinitis
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A llergic rhinitis (AR), characterized by nasal congestion,rhinorrhea, sneezing, and itching, is among the most
common allergic diseases in the United States, with prevalence
estimated between 20 and 40 million people, and is the cause
of approximately 14 million physician ofﬁce visits each
year.1Y4 In the United States, AR is associated with an estimat-
ed $4.5 billion in direct costs and 3.8 million days of lost work
or school.5Y7 In Europe, the annual direct cost of AR is esti-
mated at E1.29 billion.8 The disease causes signiﬁcant dis-
comfort and has a substantial impact on patient quality of life,
contributing to sleep disorders, fatigue, mood disorders, sex-
ual dysfunction, substantially reduced work performance, and
days lost at work.9Y15 School attendance also suffers as a
result.16,17 Intranasal corticosteroids (INS) are recommended
as ﬁrst-line therapy for AR because of their demonstrated ef-
ﬁcacy in reducing AR symptoms and favorable safety proﬁle
compared with systemic corticosteroids.18Y20
Patient compliance with a prescribed treatment regimen
can signiﬁcantly affect its ultimate success; this is particular-
ly true of INS, which must be used regularly to be effective.
Patient acceptance of, and satisfaction with, the therapeutic
regimen are therefore extremely important. Results of recent
studies indicate that patients’ perceptions of INS are inﬂu-
enced not only by sensory attributes of the agent but also by
the ease and comfort of its administration.21Y23 Important fea-
tures that could affect patient adherence include differences in
delivery devices, handling characteristics, and ease of use. Be-
cause a positive correlation between patient preference and
compliance has been noted, it is important to consider patient
acceptability when deciding which INS to prescribe.14,21,24,25
Mometasone furoate nasal spray (MFNS) is an INS in-
dicated for the treatment of nasal symptoms associated with
seasonal and perennial AR in adults and in children aged
2 years or older. It is also indicated for prophylaxis therapy for
seasonal AR in adults and adolescents aged 12 years or
older.26 The objective of the present survey was to determine
whether the characteristics of the MFNS delivery device are
an impediment to its use.
METHODS
Subjects
This ease-of-use survey was conducted by Synovate on
behalf of Schering Labs, a division of Schering Corporation.
A random sample of preidentiﬁed MFNS users was recruited
from the Synovate interactive national panel through e-mail
invitations asking for their participation in the study. Online
interviews were conducted in November 2006.
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Assessments
Respondents were asked 11 questions assessing their
attitudes about ease of use of MFNS (Table 1). To determine
which characteristics were most important to users, respon-
dents were asked to make a more critical assessment of product
attributes through a maximal differential technique, based on a
Latin square (balanced order and pairing) design. Respondents
viewed 5 claims about product attributes at once and were asked
to select which were the most important and which were the
least important attributes. Each claim was exposed and reacted
to 3 times, providing a more robust evaluation than a single
assessment. The analysis for each criterion was summarized
into 1 measure. The maximal differential analysis does not use a
scale; it derives measures without rating the claim.
RESULTS
Subjects
The random sample included 1544 respondents, of
whom 506 were pediatric (aged 2Y17 years; half were admin-
istered MFNS by a caregiver and half self-administered
MFNS), 355 were elderly, and 562 (including 227 elderly)
were arthritis sufferers (some respondents may have been in
more than 1 group). The demographics of the sample popu-
lation are summarized in Table 2.
Total Sample
In the total sample, 98% reported that MFNS is easy to
use, 96% reported that the mist from the applicator is easy to
administer, and 96% reported that the applicator is easy to pump
and press (Table 3). Similar numbers were noted for the
questions about the applicator’s comfort in the hand. Overall,
85% of total users said that they liked using the MFNS pump
bottle.
Pediatric Users
Among pediatric users, 96% of those who administer
MFNS themselves said that the Bapplicator ﬁts comfortably
in the nostril[; 92% of caregivers agreed with that statement.
Nearly 100% of those in both groups reported that MFNS is
easy to use, and more than 90% said that it was easy to admin-
ister and that the applicator was comfortable to hold. However,
although 93% of caregivers reported that they liked using the
MFNS pump bottle, only 77% of self-users agreed with that
statement, the lowest percentage of any of the subgroups.
Elderly Users and Users With Arthritis
Nearly all elderly users and users with arthritis agreed
that the Bapplicator ﬁts comfortably in the nostril[ (96% and
97%, respectively) and is Bappropriately sized to administer
the medicine[ (97% and 96%, respectively). These rates were
similar to those of the general users. Both subgroups found
MFNS easy to administer (Q95%) and to pump/press (95%).
Ninety-ﬁve percent of elderly users and 93% of users with
arthritis reported that the applicator was comfortable to hold
and ﬁt well in the hand. The response rate to Blike using the
MFNS pump bottle[ was 84% for elderly users and 83% for
users with arthritis.
Maximum Differential Analysis
All categories of MFNS users selected ease of adminis-
tration features such as Bthe mist is easy to administer,[ Bis easy
TABLE 1. Survey Questions About Ease of Use of the MFNS
Applicator*
1. Do you find MFNS easy to use?
2. Do you find MFNS easy to store?
3. Would you say MFNS is easy to keep clean/maintain?
4. Would you say MFNS is easy to pump/press?
5. Do you find the mist from MFNS easy to administer?
6. Do you feel that MFNS fits comfortably in the hand?
7. Do you find MFNS comfortable to hold while administering a dose
(or mist in the nose)?
8. Would you say MFNS fits well in the hand when administering a dose
(or mist in the nose)?
9. Would you say the MFNS applicator fits comfortably in the nostril?
10. Would you say you like using the MFNS pump bottle?
11. Would you say the nozzle is appropriately sized to administer
the medicine?
*The survey questions were asked in the order presented here.












e18 509 (33) 56 (5) 506 (100)
18Y34 108 (7) 203 (18) 22 (4)
35Y44 139 (9) 236 (21) 45 (8)
45Y49 139 (9) 191 (17) 67 (12)
50Y64 448 (29) 372 (33) 153 (43) 303 (54)
Q65 201 (13) 68 (6) 202 (57) 124 (22)
Sex
Female 988 (64) 709 (63) 253 (50) 266 (75) 438 (78)
Male 309 (20) 304 (27) 89 (25) 124 (22)
No answer 247 (16) 101 (9) 253 (50)
Values were expressed as no. (%).
*There were 2 subgroups within the pediatric sample of the study. Half of the pediatric patients self-administered MFNS, and half had MFNS administered by a caregiver (ie, parent).
Of those administered by a caregiver, 100% were female (mother of the child). For those who self-administered, because of the children’s age (G18 years), sex and other demographic
information were not provided.
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to use,[ and Bis easy to pump/press[ as the most important at-
tributes (Table 4). Other characteristics considered important
among pediatric caregivers, the elderly, and users with arthritis
included Bthe applicator ﬁts comfortably in the nostril[ and Bis
appropriately sized to administer the medicine.[ The least im-
portant characteristic was Bis easy to store.[
DISCUSSION
Individual product attributes of different INS are read-
ily distinguishable by patients. Patient acceptance and satis-
faction with these attributes may inﬂuence their medication
preferences and, ultimately, treatment adherence. One survey
conducted in 2000 adults with AR found that 80% of respon-
dents were noncompliant with a range of treatments for various
reasons, including that the medication was inconvenient to
take.27 A lack of adherence to INS therapy can then lead to in-
adequate treatment of AR and subsequent problems such as a
greater number of ofﬁce visits and decreased productivity and
increased absenteeism at work or school.28 In light of these
facts, the results of this survey, showing that the great major-
ity of patients using theMFNS applicator agree that it is easy to
use, are important.
This survey reports data for subgroups of INS users: pe-
diatric patients, elderly patients, and individuals with arthritis.
The results support those of a recent product accessibility study
conducted on behalf of the Arthritis Foundation, where MFNS






























MFNS is easy to store (Q2) 98 98 98 98 98 99 98
MFNS is easy to use (Q1) 98 98 98 99 98 97 97
MFNS is easy to keep clean/maintain (Q3) 97 97 96 97 95 96 97
MFNS applicator fits comfortably in the
nostril (Q9)
96 97 94 92 96 97 98
MFNS is easy to pump/press (Q4) 96 96 96 95 96 95 95
The mist from MFNS is easy to administer (Q5) 96 96 96 97 95 95 95
MFNS fits comfortably in the hand (Q6) 96 96 97 97 96 97 96
The nozzle is appropriately sized to administer
the medicine (Q11)
95 96 93 91 94 97 96
MFNS is comfortable to hold while administering
a dose (or mist in the nose) (Q7)
94 94 94 95 93 95 93
MFNS fits well in the hand when administering
a dose (or mist in the nose) (Q8)
94 94 95 96 93 95 93
I like using the MFNS pump bottle (Q10) 85 85 85 93 77 84 83
Values were presented as the percentage of users with positive answers to questions.
*The attributes were listed by general order of derived importance rather than by question number.


















The mist from MFNS is easy to administer 177 179 178 181 178 175
MFNS is easy to use 168 170 164 176 170 166
MFNS is easy to pump/press 157 160 154 167 158 156
The MFNS applicator fits comfortably in the nostril 144 150 154 145 144 143
The nozzle is appropriately sized to administer the medicine 128 135 144 126 126 126
MFNS is comfortable to hold while administering a dose
(or mist in the nose)
95 84 81 88 93 97
MFNS fits well in the hand when administering a dose
(or mist in the nose)
81 73 72 74 81 85
MFNS is easy to keep clean/maintain 79 82 92 72 78 79
MFNS fits comfortably in the hand 42 38 36 40 42 45
I like using the MFNS pump bottle 42 38 38 39 41 41
MFNS is easy to store 15 14 16 12 14 16
*The ranking data in this table were derived from patients’ selection of most important survey statements, with the larger numbers identifying the most important; the methodology
used was a maximum differential analysis.
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was evaluated by 8 subjects with arthritis (mean age, 65 years)
to determine accessibility and ease of use. Ten tasks were
administered: 6 tasks were related to opening the package and
reading information and 4 tasks were related to physical use.
Subjects ratedMFNS on a scale ranging from 1 = not at all easy
to use to 5 = extremely easy to use. The mean overall score
for all 10 tasks was approximately 4.25, indicating a high de-
gree of ease of use of MFNS among patients with arthritis.
CONCLUSIONS
Among all categories of MFNS users in this survey,
greater than or equal to 97% reported that MFNS is easy to
use. Nearly all pediatric users, elderly users, and users with ar-
thritis agreed that the applicator ﬁts comfortably in the nos-
tril and is appropriately sized to administer the medicine, and
that the drug is easy to administer. The high ratings given to
the ease of use of MFNS in this survey may support provid-
ers in their efforts to improve patients’ adherence to AR treat-
ment regimens.
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